Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.

Clark JI, Gaynor ER, Martone B, Budds SC, Manjunath R, Flanigan RC, Waters WB, Sosman JA
Clin Cancer Res. 1999 5 (9): 2374-80

PMID: 10499607

MeSH Terms (16)

Aged Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Injections, Subcutaneous Interferon-alpha Interferon alpha-2 Interleukin-2 Kidney Neoplasms Male Middle Aged Pilot Projects Recombinant Proteins

Connections (1)

This publication is referenced by other Labnodes entities: